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ABSTRACT
The Philadelphia chromosome-negative (Ph-
negative) myeloproliferative neoplasms (MPNs) 
p o l y c y t h a e m i a  v e r a  ( P V ) ,  e s s e n t i a l  
thombocythaemia (ET) and primary myelofibrosis 
(PMF) are clonal disorders of multipotent 
haematopoietic progenitors. The genetic cause of 
these disorders was not fully defined until a somatic 
activating mutation in the JAK2 non-receptor 
tyrosine kinase, JAK2V617F, was identified in most 
patients with PV and significant proportion of 
patients with ET and PMF. The discovery of JAK2 
mutation has changed the molecular reclassification 
of MPNs. This also provideda genomic target for 
therapeutical approach. A number of JAK2 
inhibitors have been developed and tested for 
MPNs. Several JAK2 inhibitors have reached the 
stage of clinical trial and includedpatients with 
intermediate-risk or high-risk MF. This population 
of MF is best candidate for trials because currentlyit 
has no effective therapy and thesurvival is 
significantly poor. Considering all clinical data on 
Ph-negative MPNs, JAK2 inhibitors give a clinical 
benefit of spleen reduction in  approximately 40-
50% of patients and abolished symptoms in vast 
majority of MF cases. The most developed among 
JAK2 inhibitors is Ruxolitinib, which has 
demonstrated clinical improvement with well 
tolerated toxicities.However, JAK2 inhibitor was 
equally active in patients with and without JAK2 
mutation. Other JAK2 inhibitors are less developed 
but showed a similar clinical benefit. The effect on 
the natural course of MF in treated patients needs to 
be further investigated.
INTRODUCTION
Myeloproliferative disorders (MPD), recently 
renamed as myeloproliferative neoplasms (MPNs), 
are clonal disorders of transformedmultipotent 
hematopoietic stem cellswhich manifest clinically 
by uncontrolled myeloid proliferation.These 
proliferative syndromes include chronic myeloid 
leukaemia (CML), polycythaemia vera (PV), 
essential thrombocythaemia (ET) and primary 
myelofibrosis (PMF), as well as chronic 
eos inophi l ic  leukaemia  (CEL),  chronic  
myelomonocytic leukaemia (CMML), and systemic 
mastocytosis (SM) and others.Although each of the 
MPN is identified as a distinct clinicopathological 
existence, these disorders share common features 
that discriminate them from other myeloid 
malignancies such as myelodysplastic syndromes 
(MDS) and acute myeloid leukaemia (AML). These 
featuresincludebiology and clinical characteristics. 
Biologically, MPNs involve a multipotent 
hematopoietic stem cell with a dominance of the 
transformed clone over nontransformed progenitors 
and hypercellularity of the marrow, with apparently 
unstimulated overproduction of one or more of the 
formed elements of blood. Clinically, they have an 
increased risk of thrombosis and bleeding and 
spontaneous transformation to acute leukemia and 
marrow fibrosis.
Detection of mutant alleles in CML, 
CMML, CEL and SM, led to observations that 
constitutive activation of tyrosine kinase signalling 
was induced by the mutation. A clear example of 
these mutated kinases is the product of the 
Philadelphia (Ph) chromosome, the BCR 
(breakpoint cluster region)–ABL (Abelson murine 
l e u k e m i a )  f u s i o n  t y r o s i n e  k i n a s e  i n  
CML.Accumulating dataafterwarddemonstrated 
that tyrosine kinase signalling activation is a 
common pathogenetic mechanism in MPNs and that 
these mutated kinases might serve as targets for 
molecular treatment approaches.
In contrast to the cause of CML the 
pathogenesis of other MPNs is less clear.A key 
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Generally, testing for the JAK2 V617F 
mutation includes allele-specific polymerase chain-
reaction (PCR) assay, pyrosequencing, restriction-
enzyme digestion, and real-time PCR. The assays 
are sensitive to detect the presence of a 
heterozygous mutation in as few as 5 to 10% of cells 
and have low rates of false positivity. These 
properties make them useful for diagnostic purpose.
After the finding of V617F JAK mutant, 
many other mutations have been observed in 
JAK2V617F-negative MPNs, both inchronic phase 
(exon 12 mutations of JAK2, MPL, TET2, LNK, 
EZH2) and blast phase (NF1, IDH1, IDH2, ASXL1, 
CBL, Ikaros). Some of the mutations involve 
JAKSTAT signaling activation while others involve 
c h r o m a t i n  r e m o d e l i n g  a n d  l e u k e m i c  
transformation.One well characterized mutation is 
the cytokine transmembrane receptor MPL (MPL 
W515). MPL W515 mutationis found in 3% patients 
of ET and about 10% cases with JAK2V617F-
negative PMF, but not in PV. The mutated gene 
expression results in factor-independent growth and 
constitutive activation of downstream signaling 
proteins including the STAT, MAP kinase, and 
phosphatidylinositol 3-kinase transduction 
pathways. Similar to JAK2V617F mutation JAK2 
exon 12 mutant kinases bind cytokine receptors and 
are phosphorylated in the absence of ligand, and 
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Table 1. Frequency of the JAK V617F allele in myeloid disorders.
Disease   Frequency











Acute myeloid leukemia# <5%
*Most common in patients with refractory anaemia with ringed sideroblasts and 
thombocytosis, a clinically distinct subtype of myelodysplastic syndromes. #Most 
common in patients with a previous history of  polycythaemia vera, essential 
thrombocytopaenia and primary myelofibrosis.
lead to ligand-independent activation of 
downstream signalling pathways.
Furthermore, activation of signalling by the 
JAK2V617F kinase might partly be due to loss of 
negative-feedback mechanisms which is important 
in altering JAK2 signalling. JAK activity is 
negatively regulated by the suppressor cytokine 
signaling (SOCS) family of proteins, which 
normally bind to the JAK kinases resulting in their 
degradation. Two important proteins, SOCS1 and 
SOCS3, have capabilities in binding to JAK2 and 
inhibiting JAK2 catalytic activity. Expression of 
SOCS1 results in JAK2 and JAK2V617F 
degradation and inhibition of kinase activity 
whereas the expression of SOCS3 results in 
increased JAK2V617F protein stability, increased 
SOCS3 phosphoryla t ion  and increased  
JAK2V617F phosphorylation.
An observation of significant correlation 
between JAK2V617F and disease duration 
indicates that JAK2V617F occurs after the 
appearance of the MPN phenotype as a mutation 
associated with disease progression but is not 
sufficient to cause the phenotype. The correlation 
between the presence of the mutation and increased 
frequency of disease complications could also be 
linked to a more aggressive phenotype mediated by 
the mutation. Taken together, MPNs are genetically 
heterogeneous with unclear molecular basis.
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Figure 5. Molecular structure of TG101209 and its selective inhibition of JAK2 kinase. (a) Chemical structure of TG101209 
(molecular formula,C26H35N7O2S; molecular weight, 509.7; melting point 2431C). (b) Molecular model depicting docking of 
TG101209 in the JAK2 ATP pocket. The shaded surface illustrates hydrophobic (red) and hydrophilic (blue) portions of the protein. 
Key inhibitor–protein interactions, including the hydrogen bond with the hinge Leu932 residue, the hydrophobic contacts in the 
shallow angular pocket lined by residues Met929, the methylene groups of Lys882, and the initial portion of the DFG (AspPheGly) 
(Asp994 shown) activation loop, as well as the hydrogen bond with the NH of the sulfonamide from TG101209 with Asn981 are 
shown. (c) TG101209 inhibitory activity (IC50) against select kinases in the in vitro kinase assay.
Rational concept of JAK2 inhibitor treatment in 
MPD
Despite incomplete understanding of the 
molecular basis of MPNs, JAK2 remains an 
attractive target for drug development. Mutations 
with a gain of function of JAK2, MPL, CBL and 
those with a loss of function of LNK and NF1 
activate the JAKSTAT pathway leading to a final 
phenotype of MPN with alteration of immune 
response, inflammation, angiogenesis, proliferation 
and resistance to apoptosis.The character of 
resistance to apoptosis was supported by in vitro 
studies demonstrating that smallmolecule inhibitors 
of JAK2 inhibit the proliferation of cell lines 
carrying JAK2V617F. This inhibition is dose 
dependent and reduces the phosphorylation of 
JAK2 and STAT5 downstream signaling pathways 
resulting in induction of apoptosis. Even in patients 
without a confirmed JAK2 mutation, the detection 
of STAT activation indicates dysregulated JAK2 
activity. Thus, regardless of the mutational status of 
JAK2, the malignant cells retain their 
responsiveness to JAK2-activating cytokines 
and/or growth factors and  might benefit from JAK2 
inhibition.
Generally JAK2 inhibitorscan be 
categorized into two classes, JAK2-selective 
inhibitor (class I) and non-JAK2 selective inhibitor 
(class II). Class I inhibitors primarily target JAK2 
kinase (including JAK2V617F) whereas class II 
inhibitors were developed for non-MPD indications 
but still have therapeutic potential in MPD given 
their significant 'off-target' JAK2 kinase-inhibitory 
activity. For class I inhibitors, pharmacological 
strategy has been to refine an existing tyrphostin 
(tyrosine phosphorylation inhibitor) scaffold based 
on available molecular structural data for JAK2 and 
JAK3 kinase domains,to design compounds that 
selectively bind to the JAK2 (relative to JAK3) 
kinase catalytic site at low nanomolar 
concentrations,as displayed in figure 5. As a 
consequence,these compounds can potently 
inhibitboth wild-type (JAK2WT) and mutant 
(JAK2V617F) alleles. A cell-based screen was 
developed to identify allelespecific inhibitors of 
JAK2V617F-negative. These have the potential for 
a more optimal therapeutic window because the 
developed compound will only inhibit  the disease 
allele.Vast majority of JAK2 inhibitors are small 
molecules that act by competing with ATP for the 
ATP-binding catalytic site in the kinase domain.
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